Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life SciencesNSE:RPGLIFE -1.33%93 ROC (Joel Greenblatt) % is 50.66% as of Jun. 2026, which is 14% above its 10-year median of 44.43. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 93/100 and a GF Value™ of ₹2,450.92 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 982 Drug Manufacturers companies, RPG Life Sciences ranks better than 86.15% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. RPG Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 50.66%.
The historical rank and industry rank for RPG Life Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:RPGLIFE'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.39 Med: 44.43 Max: 101.62
Current: 55.82
During the past 13 years, RPG Life Sciences's highest ROC (Joel Greenblatt) % was 101.62%. The lowest was 13.39%. And the median was 44.43%.
NSE:RPGLIFE's ROC (Joel Greenblatt) % is ranked better than 86.15% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.405
vs NSE:RPGLIFE: 55.82
RPG Life Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 11.70% per year.
RPG Life Sciences (NSE:RPGLIFE) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
RPG Life Sciences ROC (Joel Greenblatt) % Related Terms
RPG Life Sciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RPGLIFE vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's ROC (Joel Greenblatt) % falls into.
RPG Life Sciences ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 50.66% mean?
RPG Life Sciences (NSE:RPGLIFE) has a ROC (Joel Greenblatt) % of 50.66% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on RPG Life Sciences and its competitors. This is 14% above median its historical median of 44.43. Over the past decade, RPG Life Sciences' ROC (Joel Greenblatt) % has ranged from 13.39 to 101.62. According to the industry distribution chart, RPG Life Sciences ranks #136 out of 982 companies in the Drug Manufacturers industry, placing it in the top 13.8%.
Is RPG Life Sciences' ROC (Joel Greenblatt) % too high?
RPG Life Sciences' current ROC (Joel Greenblatt) % of 50.66% is 14% above median its 10-year median of 44.43. Over the past 10 years, this metric has ranged from a low of 13.39 to a high of 101.62. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.41. RPG Life Sciences' value of 50.66% is 344.2% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #136 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, RPG Life Sciences has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #136 out of 982 companies for ROC (Joel Greenblatt) %. This places RPG Life Sciences in the top 14% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.41. RPG Life Sciences' value of 50.66% is 344.2% above this benchmark. Historically, RPG Life Sciences' own ROC (Joel Greenblatt) % has ranged from 13.39 to 101.62 over the past decade. While the company's 10-year median is 44.43 vs. the industry median of 11.41, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current ROC (Joel Greenblatt) % of 50.66% is 344.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current ROC (Joel Greenblatt) % is 50.66%, which is 14% above median its own 10-year median of 44.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,450.92, compared to a current price of ₹2,850.20 — trading 16.3% above its estimated fair value. The current ROC (Joel Greenblatt) % is 50.66%, which is 14% above median its 10-year median of 44.43 and 344.2% above the Drug Manufacturers industry median of 11.41. RPG Life Sciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current ROC (Joel Greenblatt) % is 50.66% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,850.20 is trading 16.3% above its estimated GF Value™ of ₹2,450.92.
GuruFocus considers RPG Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:RPGLIFE:
ROC (Joel Greenblatt) %: 50.66% (14% above median its 10-year median of 44.43)
GF Value™: ₹2,450.92 vs. price of ₹2,850.20 (16.3% above fair value)
Industry Position: 344.2% above the Drug Manufacturers median (#136 of 982)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
93GF Score
Get the complete analysis for NSE:RPGLIFE
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
